Recent Updates
Recently added Catalysts

Galcanezumab

Phase 3

Episodic Cluster Headache | Small molecule | Other |Eli Lilly and Company|Last Updated: Feb 10, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment274
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02797951A Study of LY2951742 (Galcanezumab) in Participants With Cluster HeadachePHASE3 COMPLETED 165Jul 13, 2016Jan 21, 2021Feb 10, 202240 United States, Belgium +10
NCT02397473A Study Of Galcanezumab In Participants With Episodic Cluster HeadachePHASE3 COMPLETED 109May 22, 2015Jun 4, 2018Sep 9, 201947 United States, Belgium +10
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
Baseline through End of Study (Up to 4 Years)

A TEAE is defined as the reported AEs that first occurred or worsened during the post-baseline phase compared with the baseline phase. An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect, Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. A summary of serious and other non-serious adverse events regardless of causality is located in the reported adverse events module.

Number of Participants With Suicidal Ideation and Behaviours Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)
Baseline through End of Study (Up to 4 Years)

C-SSRS is a scale capturing occurrence, severity, and frequency of suicide-related thoughts and behaviours, and has a binary response (yes/no). * Suicidal Ideation: a "yes" answer to any one of 5 suicidal ideation questions: Wish to be Dead, Non-specific Active Suicidal Thoughts, Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act, Active Suicidal Ideation with Some Intent to Act, without Specific Plan, Active Suicidal Ideation with Specific Plan and Intent. * Suicidal Behaviour: a "yes" answer to any of 5 suicidal behaviour questions: Preparatory Acts or Behaviour, Aborted Attempt, Interrupted Attempt, Actual Attempt (non-fatal), Completed Suicide.

Overall Mean Change From Baseline in Number of Weekly Cluster Headache Attacks
Baseline, Week 1 through Week 3

Number of cluster headache attacks was recorded daily by study participants in their ePRO Diary. Overall mean change from baseline is derived from the average of weeks 1 to 3 from mixed model repeated measures (MMRM) analysis. Least Square (LS) means were calculated using MMRM model with treatment, sex, pooled investigative site, week, baseline, and treatment by week as fixed effects.

Secondary Endpoints
Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA) to Galcanezumab
Baseline through End of Study (Up to 4 Years)
Percentage of Participants With 50% or Greater Reduction From Baseline in the Weekly Number of Cluster Headache Attacks
Baseline, Week 3
Overall Mean Change From Baseline in Number of Weekly Cluster Headache Attacks
Baseline, Week 1 through Week 8
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
GalcanezumabEXPERIMENTALParticipants received 300 milligram (mg) Galcanezumab administered subcutaneously (SC) up to once a month.
Galcanezumab 300mgEXPERIMENTALGalcanezumab 300mg administered subcutaneously (SC) every 30 days during an 8 week treatment period.
PlaceboPLACEBO_COMPARATORPlacebo administered SC every 30 days during an 8 week treatment period.
Interventions
NameTypeDescription
GalcanezumabDRUGAdministered SC
PlaceboDRUGAdministered SC
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites40

Inclusion Criteria: * Participants who participated in and completed either study CGAL or study CGAM. * Investigator judges the participant as reliable to follow all study procedures, keep all study visits, and be compliant with study requirements. Exclusion Criteria: * Current enrollment in or d...

Countries:United StatesBelgiumCanadaDenmarkFinlandFranceGermanyGreeceItalyNetherlandsSpainUnited Kingdom
Unlock Eligibility Criteria